Influence of recombinant interleukin-2 and alpha- and gamma-interferons on the induction of novel class I antigens

Journal of Immunogenetics
Y MitsuishiM M Tongio

Abstract

Previous results obtained in our laboratory showed that novel class I antigens, closely related to HLA-A (TM antigen related to HLA-A9 and GO antigen related to HLA-A24), were expressed on activated HLA-A9 or HLA-A24 peripheral blood lymphocytes (PBL), whatever activation factor was used [mitogenic stimulation (PHA, PWM, Con A), EBV transformation or alloactivation], but not on resting T and B lymphocytes. These antigens were also expressed on HLA-A9 or HLA-A24 common acute lymphoblastic leukaemias (cALL) and some 'immature' chronic lymphocytic leukaemias (B-CLL), but not in hairy cell leukaemias (HCL), most of the B-CLL, acute myeloblastic leukaemias (AML) and acute myelomonoblastic leukaemias (AMoL). In order to investigate the regulation mechanisms of these novel class I antigens, PBL and different leukaemic cell types were treated in vitro with recombinant IL-2 (rIL-2) and alpha and gamma-interferon (rIFN). Our results showed that without previous activation, but after culture with rIL-2, TM and GO antigens could be induced in HLA-A9 or HLA-A24 PBL and enhanced in HLA-A9 or HLA-A24 B-CLL cases, whereas no expression was found in HLA-A9 or HLA-A24 HCL, T-ALL, AML or AMoL. After culture with rINFs, the expression of TM and GO...Continue Reading

References

Mar 1, 1987·Annales De L'Institut Pasteur. Immunology·R J Poljak
Feb 1, 1989·Immunology Today·N Holmes
Jan 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·A RashidbaigiS Pestka
Feb 1, 1985·Proceedings of the National Academy of Sciences of the United States of America·K A Smith, D A Cantrell
May 1, 1987·Proceedings of the National Academy of Sciences of the United States of America·P PaulD Cohen
Aug 1, 1987·Journal of Immunogenetics·T CrepaldiP Richiardi
Sep 1, 1986·Human Immunology·R FauchetD J Charron
May 1, 1985·The Journal of Experimental Medicine·O LantzJ C Brouet
Apr 1, 1985·Immunology Today·G Trinchieri, B Perussia
Jul 1, 1984·Immunology Today·R J Robb
Sep 1, 1984·Immunology Today·F Rosa, M Fellous
Jan 1, 1984·Immunology Today·G G Klaus, C M Hawrylowicz

❮ Previous
Next ❯

Citations

Aug 29, 2013·ISRN Dermatology·Hataichanok PandithSeung Joon Baek

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

B-Cell Leukemia (Keystone)

B-cell leukemia includes various types of lymphoid leukemia that affect B cells. Here is the latest research on B-cell leukemia.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.